Category: Nuclear Medicine

Nuclear Medicine

Latest

Toshiba Introduces Latest PET/CT System

Oncologists have access to advanced imaging technologies for cancer patient care with the new Celesteion PUREViSION edition PET/CT system from Toshiba Medical. The newest edition of Celesteion allows for ease and efficiency in PET/CT, CT simulation, and diagnostic CT exams, to help diagnose and treat oncology patients.

Market Analysts Report Increased Clinical Use of Hybrid Imaging Platforms

According to a report from market analysis company Frost & Sullivan, hybrid imaging platforms represent a significant advancement for clinicians by presenting them with both anatomical and physiological images of patients’ organs, tissues, and tumors in a single scan. Market analysts report that these platforms have widespread applications in cardiology, oncology, brain imaging, drug discovery and personalized medicine.

Read More

Open PET/CT System Improves Imaging Experience for Cancer Patients

A new cancer care center in Wisconsin recently installed the Celesteion PET/CT system from Toshiba America Medical Systems Inc to provide patients with more accurate PET/CT scans. The new Fox Valley Hematology & Oncology’s (FVHO) Health & Wellness Center, which opened in September 2015, will use the Celesteion PET/CT system to image and plan treatment for cancer patients, as well as open up a new service line in the future for orthopedic imaging.

Read More

Recently Launched PET/CT System Creates Super-fine, Low-dose Images

Neusoft Medical Systems Co Ltd, based in Shenyang, China, recently launched its CE-certified and FDA-approved NeuSight PET/CT system for global markets. The NeuSight PET/CT system has the capability to create super-fine and low-dose images, which can provide accurate diagnostic information with fast acquisition and post processing speeds.

Read More
Loading

Nuclear Medicine

Latest

Report: Strong Growth for PET, SPECT

A new report from market research firm TechNavio forecasts a compound annual growth rate of nearly 6% through 2019 for key nuclear imaging modalities, PET and SPECT.